Terbinafine-induced liver toxicity in the context of a SARS-CoV-2 pandemic: a case report

• Autores: Bustios Sanchez, Carla, Sumire Umeres, Julia, Asato Higa, Carmen, Monge Zapata, Victor
• Formato: artículo
• Fecha de Publicación: 2021
• Institución: Sociedad de Gastroenterología del Perú
• Repositorio: Revista de Gastroenterología del Perú
• Lenguaje: español
• OAI Identifier: oai:ojs.revistagastroperu.com:article/1280
• Enlace del recurso: http://www.revistagastroperu.com/index.php/rgp/article/view/1280
• Nivel de acceso: acceso abierto
• Materia: Acute liver injury; drug-induced; Terbinafine; SARS-CoV-2; Daño hepático inducido por medicamentos; Terbinafina

Terbinafine is a drug that can induce acute liver damage. We present the case of a 40-year-old male patient who developed liver dysfunction after 35 days of terbinafine treatment for onychomycosis. The anatomopathological study showed: acute hepatitis in resolution, in addition to ductopenia and cholestasis. These findings, without a history of viral or autoimmune hepatitis, are consistent with the diagnosis of drug-induced liver damage (DILI). In this report we present the first case in our country of a patient who is affected by an acute liver disease: terbinafine-induced liver injury, to which SARS-CoV-2 infection was later associated in the context of a pandemic.